Trial of ferric carboxymaltose in heart failure does not meet primary endpoint

Belgique Nouvelles Nouvelles

Trial of ferric carboxymaltose in heart failure does not meet primary endpoint
Belgique Dernières Nouvelles,Belgique Actualités
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 12 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 51%

Ferric carboxymaltose (FCM) did not improve a hierarchical outcome of death, heart failure hospitalizations and exercise function in ambulatory patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.

retrieved 28 August 2023 from https://medicalxpress.com/news/2023-08-trial-ferric-carboxymaltose-heart-failure.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

medical_xpress /  🏆 101. in UK

Belgique Dernières Nouvelles, Belgique Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Intravenous ferric carboxymaltose linked to lower risk of heart failure hospitalizations in iron-deficient patientsIntravenous ferric carboxymaltose linked to lower risk of heart failure hospitalizations in iron-deficient patientsIn iron-deficient patients with heart failure and reduced or mildly reduced left ventricular ejection fraction, intravenous ferric carboxymaltose (FCM) is associated with a reduced risk of the composite outcome of total cardiovascular hospitalization and cardiovascular death through 52 weeks compared with placebo, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.
Lire la suite »

CRT-D upgrade reduces morbidity and mortality in HFrEF patients with RV pacingCRT-D upgrade reduces morbidity and mortality in HFrEF patients with RV pacingUpgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and mortality and improves left ventricular (LV) reverse remodeling compared to an implantable cardioverter-defibrillator (ICD) in select patients with heart failure and reduced ejection fraction (HFrEF) and intermittent or permanent right ventricular (RV) pacing, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.
Lire la suite »

First randomized trial of traditional Chinese medicine for heart failure shows benefitFirst randomized trial of traditional Chinese medicine for heart failure shows benefitThe traditional Chinese medicine qiliqiangxin reduces hospitalization for heart failure and cardiovascular death in patients with heart failure and a reduced ejection fraction (HFrEF), according to late breaking research presented in a Hot Line session August 26 at ESC Congress 2023.
Lire la suite »

Last Irish witch trial to 'come alive' at NI museumLast Irish witch trial to 'come alive' at NI museumTrial of the 'Islandmagee witches' saw eight women and one man found guilty of witchcraft in 1711
Lire la suite »

Trump’s lawyers to argue for trial to be delayed until 2026Trump’s lawyers to argue for trial to be delayed until 2026US District Judge Tanya Chutkan is expected to set a tentative trial date over January 6 charges.
Lire la suite »

Trump’s lawyers to argue for trial to be delayed until 2026Trump’s lawyers to argue for trial to be delayed until 2026US District Judge Tanya Chutkan is expected to set a tentative trial date over January 6 charges.
Lire la suite »



Render Time: 2025-04-06 11:06:03